Post-streptococcal glomerulonephritis associated with atypical hemolytic uremic syndrome: To treat or not to treat with eculizumab?

Aadil Kakajiwala, Tricia Bhatti, Bernard S. Kaplan, Rebecca L. Ruebner, Lawrence Copelovitch

Research output: Contribution to journalArticlepeer-review

Abstract

A 7-year-old male with poststreptococcal glomerulonephritis (PSGN) developed hemolytic uremic syndrome (HUS) and achieved remission. Hewas treated with eculizumab for 1 year. The eculizumab was discontinued and the patient remained in remission. This is the 10th reported case of PSGN associated with HUS. The histopathological feature observed at the 1-year follow-up was indistinguishable from the expected findings in an individual with healed PSGN without associated HUS. The relatively good prognosis in most prior cases and the absence of any reported recurrences strongly suggest that this form of atypical HUS does not warrant long-term eculizumab therapy.

Original languageEnglish (US)
Pages (from-to)90-96
Number of pages7
JournalClinical Kidney Journal
Volume9
Issue number1
DOIs
StatePublished - Feb 1 2016
Externally publishedYes

Keywords

  • PSGN
  • aHUS
  • complement pathway
  • eculizumab

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Fingerprint Dive into the research topics of 'Post-streptococcal glomerulonephritis associated with atypical hemolytic uremic syndrome: To treat or not to treat with eculizumab?'. Together they form a unique fingerprint.

Cite this